Aktienanalyse zu Nexentis Technologies Inc (NXTS)NXTSNexentis Technologies Inc

Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity. It operates in the Basic Materials sector.

Nexentis Technologies Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at 0.52, down 93.88% year-to-date, indicating a severe decline in value. Additionally, the RSI is at 35.781, suggesting it is oversold, but this does not guarantee a rebound. The forward P/E is 0, reflecting a lack of profitability, and the gross margin has dropped to 0% in recent quarters, showing no signs of recovery. The main risk is the declining net income, which reached -11,145,000 in Q2 2026, indicating ongoing financial distress.